Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women. |
| |
| Authors: | B C Kress I A Mizrahi K W Armour R Marcus R D Emkey A C Santora |
| |
| Institution: | Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc., San Diego, CA 92196, USA. |
| |
| Abstract: | BACKGROUND: Biochemical bone markers are sensitive to the changes in bone turnover that result from treatment of postmenopausal osteoporotic women with antiresorptive therapies. Although information is available on the use of bone markers in monitoring therapy in groups of subjects, less is known regarding how these markers perform in individual patients. METHODS: Serum bone alkaline phosphatase (bone ALP) concentrations, measured with the Tandem(R) Ostase(R) assay, were used to monitor the biochemical response of bone in postmenopausal women with osteoporosis receiving either 10 mg/day alendronate therapy (n = 74) or calcium supplementation (n = 148) for 24 months. RESULTS: Bone ALP decreased significantly from baseline at 3 months (P
|
| |
| Keywords: | |
|
|
